tiprankstipranks
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA

Vanda (VNDA) Stock Price & Analysis

411 Followers

VNDA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.30 - $6.76
Previous Close$6.24
Volume1.13M
Average Volume (3M)2.57M
Market Cap
$363.16M
Enterprise Value-$18.10M
Total Cash (Recent Filing)$388.26M
Total Debt (Recent Filing)$7.01M
Price to Earnings (P/E)
Beta0.51
Jul 31, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding58,198,273
10 Day Avg. Volume2,167,076
30 Day Avg. Volume2,573,812
Standard Deviation0.13
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.86
Price to Sales (P/S)8.02
Price to Cash Flow (P/CF)-24.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.09
Enterprise Value/Gross Profit-0.10
Enterprise Value/Ebitda-5.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

29.29%23.52%27.44%19.75%
29.29% Insiders
27.44% Other Institutional Investors
19.75% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

VNDA FAQ

What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.29 and its highest was $6.76 in the past 12 months.
    What is Vanda Pharmaceuticals Inc.’s market cap?
    Currently, no data Available
    When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
    Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Jul 31, 2024 which is in 43 days.
      How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
      Vanda Pharmaceuticals Inc. released its earnings results on May 08, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.05 by -$0.12.
        Is Vanda Pharmaceuticals Inc. overvalued?
        According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Vanda Pharmaceuticals Inc. pay dividends?
          Vanda Pharmaceuticals Inc. does not currently pay dividends.
          What is Vanda Pharmaceuticals Inc.’s EPS estimate?
          Vanda Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Vanda Pharmaceuticals Inc. have?
          Vanda Pharmaceuticals Inc. has 58,198,273 shares outstanding.
            What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
            Vanda Pharmaceuticals Inc. reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.05. Following the earnings report the stock price went down -6.53%.
              Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
              Among the largest hedge funds holding Vanda Pharmaceuticals Inc.’s share is Graham Capital Management, L.P.. It holds Vanda Pharmaceuticals Inc.’s shares valued at 111K.
                ---

                Company Description

                Vanda Pharmaceuticals Inc.

                Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
                ---

                VNDA Earnings Call

                Q1 2024
                0:00 / 0:00
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                ACADIA Pharmaceuticals
                Alnylam Pharma
                BioMarin Pharmaceutical
                Curis
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis